Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: Results from the ARBI prospective clinical trial

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 9, 2012, Pages 1569-1577

  Markopoulos, Christos ^a,b   Tzoracoleftherakis, Evagelos ^a   Koukouras, Dimitrios ^a   Venizelos, Basileios ^a   Zobolas, Vasilios ^a   Misitzis, John ^a   Xepapadakis, Grigorios ^a   Gogas, Helen ^a  

^a Hellenic Society of Breast Surgeons   (Greece)

^b NONE   (Greece)

Author keywords

Anastrozole; Aromatase inhibitors; Bisphosphonates; Bone mineral density; Breast cancer; Risedronate

Indexed keywords

ANASTROZOLE; RISEDRONIC ACID;

ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POST HOC ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT;

EID: 84866734740     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1233-z     Document Type: Article

References (44)

1. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420-432
2. Ashcroft AJ, Davies FE, Morgan GJ (2003) Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 4:284-292
3. Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810
4. Bjornerem A, Straume B, Midtby M et al (2004) Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromso study. J Clin Endocrinol Metab 89:6039-6047
5. Body JJ, Bartl R, Burckhardt P et al (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16:3890-3899
6. Brufsky AM, Bosserman LD, Caradonna RR et al (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85
7. Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001-1010
8. Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796
9. Carlson RW, Hudis CA, Pritchard KI (2006) Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw 4:971-979
10. Chen Z, Maricic M, Bassford TL et al (2005a) Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558
11. Chen Z, Maricic M, Pettinger M et al (2005b) Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer 104:1520-1530
12. Chen Z, Maricic M, Aragaki AK et al (2009) Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int 20:527-536
13. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
14. Crivellari D, Sun Z, Coates AS et al (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26:1972-1979
15. Dixon JM, Renshaw L, Young O et al (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26:1671-1676
16. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215-1223
17. ESHRE Capri Workshop Group (2010) Bone fractures after menopause. Hum Reprod Update 16:761-773
18. Fleisch H (2002) Development of bisphosphonates. Breast Cancer Res 4:30-34
19. Geisler J, King N, Dowsett M et al (1996) Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmeno-pausal women with breast cancer. Br J Cancer 74:1286-1291
20. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757
21. Gibson L, Lawrence D, Dawson C, Bliss J (2009) Aromatase inhibitors for treatment of advanced breast cancer in postmen-opausal women. Cochrane Database Syst Rev, p CD003370
22. Gnant M, Eidtmann H (2010) The anti-tumor effect of bisphospho-nates ABCSG-12, ZO-FAST and more⋯. Crit Rev Oncol Hematol 74(Suppl 1):S2-S6
23. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25: 820-828
24. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271
25. Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
26. Institute of Medicine, Food and Nutrition Board (2010) Dietary reference intakes for Calcium and Vitamin D. National Academy Press, Washington, DC
27. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T (1999) A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179-1181
28. Khosla S, Atkinson EJ, Melton LJ III, Riggs BL (1997) Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J Clin Endocrinol Metab 82:1522-1527
29. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D (2000) Hysterectomy, oophrectomy and endogenous hormone levels in older women: the Rancho Bernardo study. J Clin Endocrinol Metab 85:645-651
30. Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342
31. Markopoulos C (2010) Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials. Cancer Metastasis Rev 29:581-594
32. Markopoulos C, Tzoracoleftherakis E, Polychronis A et al (2010) Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12:R24
33. National Comprehensive Cancer Network (NCCN) (2011) Clinical Practice Guideline Guidelines in Oncology: Breast Cancer, V.2.2011, Ref Type: Serial (Book, Monograph)
34. National Institute for Health and Clinical Excellence (NICE) (2009) Early and locally advanced breast cancer: diagnosis and treatment: full guideline
35. National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC
36. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
37. O'Neill S, MacLennan A, Bass S et al (2004) Guidelines for the management of postmenopausal osteoporosis for GPs. Aust Fam Physician 33:910-919
38. Papaioannou A, Morin S, Cheung AM et al (2010) Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J 182:1864-1873
39. Powell DE, Cochrane RA, Davie MW (2011) Does anastrozole affect bone reabsorption similarly in early and late postmenopausal women? Calcif Tissue Int 88:223-230
40. Rugo HS (2008) The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 19:16-27
41. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010-2018
42. Sestak I, Cuzick J, Sapunar F et al (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9:866-872
43. Sharp CA, Evans SF, Ristelli L, Worsfold M, Davie MWJ (1996) Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmeno-pausal women. Eur J Clin Invest 26:763-771
44. Van Poznak PC, Hannon RA, Mackey JR et al (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967-975